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Simple Summary: Limited-stage (LS) small-cell lung cancer (SCLC) is a type of lung cancer that is
confined to one side of the chest without cancer spread elsewhere. The outcomes of patients with
this disease remain poor. Currently, patients with LS-SCLC are managed with chemotherapy and
radiotherapy that is delivered together. In this review article, we highlight various advancements in
treatments for LS-SCLC patients and challenges that are required to be overcome to achieve better
patient outcomes.
Abstract: Limited-stage (LS) small-cell lung cancer (SCLC) is defined as disease confined to a tolerable
radiation portal without extrathoracic metastases. Despite clinical research over two decades, the
prognosis of LS-SCLC patients remains poor. The current standard of care for LS-SCLC patients is
concurrent platinum-based chemotherapy with thoracic radiotherapy (RT). Widespread heterogeneity
on the optimal radiation dose and fractionation regimen among physicians highlights the logistical
challenges of administering BID regimens. Prophylactic cranial irradiation (PCI) is recommended
to patients following a good initial response to chemoradiation due to improved overall survival
from historical trials and the propensity for LS-SCLC to recur with brain metastases. However, PCI
utilization is being debated due to the greater availability of magnetic resonance imaging (MRI) and
data in extensive-stage SCLC regarding close MRI surveillance in lieu of PCI while spurring novel
RT techniques, such as hippocampal-avoidance PCI. Additionally, novel treatment combinations
incorporating targeted small molecule therapies and immunotherapies with or following radiation
for LS-SCLC have seen recent interest and some concepts are being investigated in clinical trials.
Here, we review the landscape of progress, limitations, and challenges for LS-SCLC including current
standard of care, novel radiation techniques, and the integration of novel therapeutic strategies
for LS-SCLC.
Keywords: limited-stage; small-cell lung cancer; radiotherapy; small molecules; immunotherapy;
clinical trials
1. Introduction
Small-cell lung cancer (SCLC) is a subtype of lung cancer accounting for 13–15% of all
lung cancer patients [1,2]. SCLC is much more prevalent in smokers [3]. Though formally
staged by the American Joint Committee on Cancer (AJCC)/Union for International Cancer
Control (UICC) TNM classification, pragmatically SCLC patients are grouped using the
Veterans Administration Lung Study Group two-stage system, dividing the cancer into
limited-stage and extensive-stage disease. Limited-stage SCLC (LS-SCLC) is cancer on the
ipsilateral hemithorax encompassable within a tolerable radiation portal and therefore is
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eligible for curative intent treatment. Extensive-stage SCLC (ES-SCLC) is cancer that either
spreads widely throughout the lungs, non-regional lymph nodes or to other organs [1].
Around 30% of patients with SCLC present with LS-SCLC [4].
Overall survival (OS) rates for SCLC patients remain particularly low. For LS-SCLC
patients, 5-year OS is about 20–35% [5,6]. The current standard of care for the treatment
of LS-SCLC is platinum-based chemotherapy with early concurrent thoracic radiation
therapy followed by prophylactic cranial irradiation (PCI) for LS-SCLC patients with good
response to initial treatment [4]. Here, we review the landscape of progress, limitations,
and challenges for LS-SCLC including current standard of care, novel radiation techniques,
and the integration of novel therapeutic strategies for LS-SCLC.
2. Current Role of Radiation in Managing LS-SCLC
2.1. Concurrent Chemotherapy with Thoracic Radiation
Concurrent thoracic chemoradiation is the mainstay of treatment for LS-SCLC re-
ceiving treatment for curative intent. The current backbone chemotherapy regimen for
LS-SCLC patients is a platinum agent with etoposide [4,7].
Concurrent chemoradiotherapy was not firmly established until the early 1990s as
clinical trials attempting to investigate this approach were not significantly powered. Two
meta-analyses published in 1992 established concurrent chemoradiation improved OS and
local disease control [8,9]. The larger of these meta-analyses, by Pignon et al. [9], included
13 clinical trials and 2140 LS-SCLC patients with a median follow up of 43 months showed
chemoradiation improved OS at 3 years by 5.4% compared to chemotherapy solely [9].
Early radiotherapy versus late radiotherapy for LS-SCLC had been previously debated.
A previous study showed late radiotherapy resulted in a higher risk of brain metastasis
compared to early radiotherapy (28% vs. 18%) [10]. Early thoracic radiation for LS-
SCLC patients also results in better 3-year progression-free survival (PFS), 3-year OS,
and 5-year OS compared to late thoracic radiation (26% vs. 19%, 30% vs. 22%, and
20% vs. 11%, respectively) [10]. A meta-analysis by Fried et al. evaluated the use of early
versus late delivery of thoracic radiotherapy to LS-SCLC patients. Seven randomized
controlled trials were evaluated which collectively showed 5% OS benefit at 2-years for
early radiotherapy [11].
2.2. Optimal LS-SCLC Radiation Fractionation
Radiotherapy dose fractionation for LS-SCLC has a long history of clinical trial devel-
opment. Published in 1999, Turrisi et al. [5] randomized 417 patients to groups that either
received hyperfractionated, twice-daily (BID) radiotherapy (1.5 Gy in 30 fractions) or a
regular fractionated once-daily regimen (1.8 Gy in 25 fractions) to receive a total of 45 Gy.
They showed that there was a significant difference with median survival; 19 months
for the once-daily group and 23 months for the BID group with an increased rate of
grade 3 esophagitis [5].
Published in 2017, the CONVERT trial did not show improved survival with the once-
daily fractionation to 66 Gy when compared to the 45 Gy in 30 fractions BID regimen [6].
The CALGB 30610/RTOG 0538 trial is evaluating high-dose once-daily 70 Gy thoracic ra-
diotherapy in comparison to the 45 Gy in 30 fractions BID regimen of thoracic radiotherapy
in LS-SCLC patients. The abstract reported June 2021 concluded that the 70 Gy arm did
not improve OS for LS-SCLC patients [12]. Though not designed as non-inferiority studies,
these two trials suggest that patients treated with once-daily fractionation appear to have
similar outcomes as patients treated with 45 Gy in 30 fractions BID.
Published in 2021, a randomized phase II clinical compared the efficacy of 45 Gy in
30 fractions BID to high-dose 60 Gy in 40 fractions BID in LS-SCLC patients. Two-year
survival was higher in the 60 Gy group with 74.2% of patients alive compared to 48.1%
in the 45 Gy group. The rates of toxicity between the two groups also did not differ
significantly [13]. Further prospective studies will be required to establish the benefit of
higher dose and fractionation in LS-SCLC patients.
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Despite the 45 Gy in 30 fractions BID regimen being supported with randomized
trial evidence, pragmatically, heterogeneity in clinical practice and utilization exists. A
pan-Canadian survey of radiation oncologists was carried out in 2016 where responses
from 52 radiation oncologists were further analyzed. For LS-SCLC patients, the most
common dose and fractionation schedule most commonly used by Canadian radiation
oncologists was 40–45 Gy in 15 once-daily fractions (40% of respondents), followed by
45 Gy in 30 BID fractions (just over 30% of respondents). 50 Gy in 25 once-daily fractions
and 60–66 Gy in 30–33 once-daily fractions were also reported at similar rates among
respondents (about 10% each, respectively) [14]. This heterogeneity of regimens and the
prevalence of 40–45 Gy in 15 once-daily fractions is likely informed by historical precedent
as evidenced by a Canadian randomized controlled trial reported in 1993 [10]. Interestingly,
a retrospective study in 2021 comparing 40 Gy in 15 fractions once daily versus 45 Gy in
30 fractions BID showed no difference in OS, locoregional recurrence, or ≥grade 3 toxicities
in LS-SCLC following propensity score adjustment [15].
A US-based survey of 309 radiation oncologists showed 60% of respondents stated
they preferred a once-daily thoracic radiation regimen and 76% stated that a once-daily
regimen was more common in clinical practice. 54.4% of respondents preferred a 60 Gy
dose when administering once-daily thoracic radiotherapy followed by 20.4% having a
preference of 66 Gy. 87.9% of US radiation oncologists preferred a total dose of 45 Gy
when administering BID thoracic radiotherapy. Respondents from academic institutions
had a higher likelihood of endorsing BID treatment in clinical practice (51% in academic
institutions vs. 33% in private practice) [16]. These surveys highlight the logistical burden
of BID schemas and preferences by physicians and patients for once-daily fractionation in
clinical care. Studies evaluating the optimal dose and fractionation regimen for LS-SCLC
patients are summarized in Table 1.
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2.3. The Role of Prophylactic Cranial Irradiation
Given the tendency for subsequent development of brain metastases from SCLC, pro-
phylactic cranial irradiation (PCI) has been recommended to LS-SCLC patients following
a good response to initial treatment with chemoradiation. The role of PCI in managing
LS-SCLC is significant; it has been shown to improve the rates of brain metastasis control
and OS [18].
While PCI has shown clinical benefit in LS-SCLC patients to reduce the rate of brain
metastasis and improve OS, randomized prospective studies for ES-SCLC and retrospec-
tive studies for LS-SCLC have also suggested that the improved sensitivity of magnetic
resonance imaging (MRI) and increased use of close imaging surveillance may diminish the
resulting OS benefit of PCI [19,20]. A 2017 phase III randomized trial for ES-SCLC showed
PCI improved the 1-year brain metastasis rate to 33% from 59%, however, there was a
lack of OS benefit with PCI as compared to the MRI surveillance only arm [20]. Further
investigations remain to ascertain whether PCI provides an OS benefit with the availability
of MRI and uptake of close imaging surveillance for LS-SCLC patients. According to
retrospective studies, another subgroup of LS-SCLC patients where the absolute benefit
of PCI may be lower are LS-SCLC patients with AJCC stage I-II disease, highlighting the
importance of obtaining TNM classification and stage for all SCLC patients [21,22].
PCI utilization rates have not been consistent and are known to differ between insti-
tutions (Table 2). A retrospective study at the Princess Margaret Cancer Centre showed
improvements in OS and brain failure free survival for those that received PCI, however
they observed some patients declined PCI due to patient or physician concerns related
to toxicity and also patients older than 65 years of age were significantly less likely to
receive PCI [23]. An updated study from the same institution showed PCI maintained
its association with OS, even in the MRI era [24]. Another study from Memorial Sloan
Kettering Cancer Center showed that patient concerns regarding neurotoxicity was the
most cited reason for the omission of PCI. Karnofsky performance status and clinical AJCC
stage were significantly associated with OS but not PCI in this retrospective study [25].
Given the associated side effects with PCI, its utility to manage LS-SCLC patients when
MRI brain surveillance is available is being questioned. In addition to the retrospective
studies highlighted above, some studies have shown no associated improvement in OS
or PFS with PCI for LS-SCLC in the MRI era [19,26] while other studies do report an OS
benefit with PCI [24,27]. Further prospective results from clinical trials that include LS-
SCLC patients, such as the SWOG S1827 MAVERICK (SWOG S1827) trial comparing PCI
to MR surveillance (NCT04155034), are awaited to provide modern prospective evidence.
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Aupérin et al., 1999 [18] 987 526 (53.2) No PCI [ref] vs. PCI
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Disease-free survival
Pooled relative risk of 0.84
(95% CI, 0.73–0.97)
Pooled relative risk of 0.46
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HR 0.76 (95% CI, 0.59–0.96)
13.3% (95% CI, 8.1–19.9) vs.
27.1% (95% CI, 19.4–35.5)
Redmond et al., 2017 [29] 20 20 (100.0) Hippocampal-sparing PCI(no comparator)
HVLT-R delayed recall at
6 months after completion
of PCI
Reliable Change Index at
6 months for HVLT-R
delayed recall
Reliable Change Index at





7.06 (SD 2.77, n = 14)
17.6%
7.10%
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thoracic BID [ref] vs. once
daily [6]
* Brain relapse times
* Median OS
3-year survival
HR 0.95 (95% CI, 0.60–1.50)
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48% (95% CI, 41–55) vs.
42% (95% CI, 36–49)
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Giuliani et al., 2010 [23] 228 127 (55.7) PCI vs. no PCI Brain FFSMedian OS
76.6% (95%, CI, 68–87) vs. 46.7%
(95% CI, 8–34)
21.7 months (95% CI, 17–36.8) vs.
11.2 (95% CI, 8.9–14.1)
Ozawa et al., 2015 [26] 124 29 (23.4) PCI vs. no PCI (with MRIand SRS salvage)
* Median OS
* Brain metastasis occurrence
rates in 2 years
25 vs. 34 months
43.0% vs. 38.4%
Qiu et al., 2016 [31] 399 185 (46.4) Early vs. late PCI
Symptomatic brain metastases
at 6, 12 and 24 months
1-year OS rates
3-year OS rates
0, 3 and 13% vs. 7, 29 and 42%
96% vs. 82%
53% vs. 35%
Lok et al., 2017 [25] 208 115 (55.0)
PCI vs. no PCI
(no significant difference








Farooqi et al., 2017 [32] 658 364 (55.3) No PCI [ref] vs. PCI Risk of deathRisk of brain metastasis
HR 0.73 (95% CI 0.61–0.88)
HR 0.56 (95% CI 0.40–0.78)
Wu et al., 2017 [22] 283 114 (41.0)
PCI vs. no PCI
(no significant difference





2-year cumulative incidence of
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Pezzi et al., 2020 [19] 297 205 (69.0) No PCI [ref] vs. PCI
* OS
* 3-year incidence rate of brain
metastasis
HR 0.844 (95% CI, 0.604–1.180)
11.20% (95% CI, 5.40–19.20) vs. 20.40%
(95% CI, 12.45–29.67)
Yan and Toh et al., 2021 [24] 369 196 (71.0) PCI [ref] vs. no PCI OSBrain failure risk
HR 1.77 (95% CI, 1.31–2.40)
HR 2.93 (95% CI, 1.85–4.63)
* no significant difference. ** study in ES-SCLC patients.
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3. Novel Radiation Approaches to Manage LS-SCLC
3.1. Intensity Modulated Radiation Therapy (IMRT)
While treatment options for LS-SCLC patients have not dramatically altered in the
last 20 years, conformal radiation techniques have improved outcomes for patients and
decreased treatment-related toxicity.
3.1.1. IMRT for Thoracic RT
Lower comformality with 2D RT and 3D conformal radiation therapy (3DCRT) in-
creases the amount of the surrounding normal tissue that receives high dose RT. As such,
there is a risk of developing higher rates of toxicities with 2D or 3DCRT such as esophagitis
or pneumonitis as compared to IMRT [33].
A retrospective study from MD Anderson Cancer Center analyzed clinical records for
223 LS-SCLC patients treated from 2000 to 2009. 119 of these patients received 3DCRT while
the remaining 104 patients received IMRT. The authors show that LS-SCLC patients who
received IMRT required significantly fewer percutaneous feeding tube insertions compared
to those who received 3DCRT (5% vs. 17%) but there were no differences in outcomes
between these two techniques [33].
3.1.2. IMRT for Hippocampal-Avoidance PCI (HA-PCI)
Given a lack of a wide variety of treatment options, further investigation is warranted
for PCI utility to find a balance between improving patient outcomes and quality of life
through the reduction in treatment-related toxicity and disease control. With the advent
of conformal RT techniques, such as IMRT or volumetric modulated arc therapy (VMAT),
selective avoidance of brain sub-structures with potential for decreased neurotoxicity rates
while maintaining disease control has become possible.
Accordingly, published in 2021, the PREMER clinical trial randomized 150 SCLC
patients (107 limited-stage and 43 extensive-stage) and showed that HA-PCI, delivered by
IMRT or VMAT, reduced the risk of worse delayed free recall (DFR) on the Free and Cued
Selective Reminding Test (FCSRT) at 3 months without any significant difference in OS and
brain metastases [34]. We also eagerly await the NRG CC003 study, which is planning to
randomize up to 400 SCLC patients (LS and ES stage) to assess the 6-month deterioration in
Hopkins Verbal Learning Test-Revised (HVLT-R) Delayed Recall associated with HA-PCI
as compared to conventional PCI.
3.2. Stereotactic Body Radiation Therapy (SBRT)
Stereotactic body radiation therapy (SBRT) has been utilized for patients with stage
I NSCLC [35–37]. There is limited evidence for the use of SBRT for LS-SCLC patients.
Given that SCLC is generally considered to be more radiosensitive compared to NSCLC,
the combination of SBRT and chemotherapy may be an option for the 5% of patients that
present with clinical stage I SCLC, however evidence is currently sparse [35].
A single-institution retrospective study in 2013 reported eight inoperable LS-SCLC
patients treated with SBRT and chemotherapy demonstrated this strategy as a safe and
effective alternative. 3-year survival and disease-free survival rates were reported at 72%
and 86%, respectively, with minimal toxicity [38]. Another small retrospective study in
2015 of six patients with stage I SCLC showed the use of SBRT to manage the primary
tumour had 100% local control at year with no associated regional nodal failure and distant
failure in the liver was reported in one patient. 1-year OS was at 63% and disease-free
survival (DFS) was 75% [39]. A multi-institutional study across 24 institutions primarily
evaluated the use of SBRT in T1-T2N0M0 SCLC patients and interrogated the benefit of
chemotherapy. Adding chemotherapy to SBRT showed an OS benefit of 31.4 months in
comparison to 14.3 months in the group without. DFS was 61.3 months in the group that
received both chemotherapy and SBRT compared to 9 months without [40].
The National Comprehensive Cancer Network (NCCN) recommends the use of SBRT
for stage I-IIA SCLC patients that do not undergo surgery. The strategy for SBRT mirrors
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those for NSCLC based on NCCN recommendations [41]. In comparison to the UK’s
National Institute for Health and Care Excellence (NICE) guidance and the Cancer Care
Ontario (CCO) guidelines, this recommendation is noticeably not present [42,43]. Due
to lack of data, currently there are no known guidelines or recommendations regarding
SBRT for the more advanced stages (i.e., IIB-IIIC) LS-SCLC. Further prospective studies are
required to adequately determine efficacy of SBRT, optimal dose and fractionation, along
with chemotherapy sequencing for the treatment of LS-SCLC patients.
3.3. Proton Beam Therapy
After correction of other prognostic factors, it has been shown for NSCLC patients that
there is a correlation between radiation therapy doses to the heart and OS [44]. This has
led to further evaluation of proton beam therapy to reduce doses of radiation to the heart
while ensuring there is adequate delivery of radiation to the lung cancer. There has been
emerging evidence for outcomes for LS-SCLC patients treated with proton beam therapy.
A single-institution prospective study investigating outcomes for 30 LS-SCLC patients that
received proton beam therapy showed a median OS of 28.2 months with limited incidence
of high-grade toxicities [45]. While these results are encouraging, further evaluation is
required in clinical trials.
3.4. Stereotactic Radiosurgery (SRS) and Whole-Brain Radiation Therapy (WBRT)
Though SCLC patients with brain metastases are considered ES-SCLC, stereotactic
radiosurgery (SRS) is worth briefly reviewing. Whole brain RT (WBRT) remains the
standard of care for SCLC patients with brain metastases and evidence for the routine use
of SRS remains limited for SCLC. In 2004, the RTOG 9508 trial reported the outcomes of
331 cancer patients with a variety of disease sites and histologies (i.e., only 6–9% patients
had small cell histology) randomized to receive WBRT alone with and without SRS boost
and identified a OS advantage for patients with a single brain metastasis treated with WBRT
and SRS boost [46]. Of note, a 2020 paper reported the First-line Radiosurgery for Small-Cell
Lung Cancer (FIRE-SCLC) multi-institutional cohort study that retrospectively evaluated
the outcomes of SRS in 710 SCLC patients [47]. Results from FIRE-SCLC comparing SRS
showed a median OS of 8.5 month and the time to central nervous system progression
(TCCP) was 8.1 months. For those with single brain metastasis, the median OS was
11 months and TCCP was 11.7 months [47]. These results suggest SRS could be an option
for selected SCLC patients and further evaluation is prospective clinical trials are warranted
for SCLC.
4. Novel Therapeutic Strategies for LS-SCLC
4.1. Targeted Therapies and Molecular Subtypes
The availability of high throughput next-generation genome sequencing technolo-
gies has allowed lung cancers to be molecularly profiled leading to the establishment of
driver mutations contributing to tumour proliferation. For example, studies have shown
that the epidermal growth factor receptor (EGFR) oncogene drives tumour growth and
proliferation in NSCLC [48–55]. Immunotherapies targeting the programmed cell death 1
(PD-1)/programmed death-ligand 1 (PD-L1) axis such as nivolumab, pembrolizumab, and
atezolizumab have shown efficacy in NSCLC [56–59].
While targeted small molecule therapies are routinely considered in the management
of NSCLC, these are not currently the mainstay of treatment for SCLC patients due to the
lack of currently targetable oncogenes with sufficient prevalence in SCLC. Rather, SCLC’s
high mutational burden is suggested to be strongly associated with tobacco exposure
with 98% of cases appearing in smokers [60]. New molecular pathways require further
investigation to establish their roles in SCLC and also whether targeted treatments improve
LS-SCLC patient outcomes. Candidate therapeutic targets in SCLC are challenging to
identify given that prevalent mutations in SCLC are mainly loss of function with the
involvement of tumour suppressor genes RB1 and TP53 [60].
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4.1.1. DNA Damage Response Inhibitors (DDR)
As the inactivation of RB1 and TP53, SCLC tumours exhibit increased susceptibility to
DNA damage. Mediators in the DNA damage response (DDR) pathway, such as poly (ADP-
ribose) polymerase (PARP), have been investigated as potential therapeutic targets [60,61].
Several studies have shown that a combination of DDR inhibitors with chemotherapy
or other targeted treatments could be a potential option for SCLC patients [62,63]. SLFN11
has been suggested as a potential biomarker of sensitivity of DNA damage chemotherapy
and PARP inhibition in SCLC [62,64–66]. After RB1 and TP53, gene amplification of
MYC is among the most common genetic abnormalities found in 20% of SCLCs [60]. A
phase II clinical trial combining paclitaxel with or without alisertib, an aurora kinase A
(AURKA) and AURKB inhibitor, showed slight improvement in PFS in a general SCLC
patient population. However, subtype analysis showed doubling of PFS in patients with
MYC-high SCLC tumours [67,68].
Lurbinectedin, an inhibitor of gene transcription and RNA polymerase II, received
FDA approval in 2020 as a second-line treatment option for SCLC [69]. Topotecan was
previously the only other option in the second-line setting but its use is limited due to
toxicity concerns and modest efficacy [70–72]. A single-arm, phase II basket trial evaluated
the efficacy of lurbinectedin in 105 SCLC patients that experienced recurrence or resistance
to initial treatment. Overall response rate by investigator assessment was 35.2% and
the rate of disease control was 68.6% [73]. The most common grade 3–4 adverse events
reported in this phase II trial were anaemia (9%), leucopenia (29%), neutropenia (46%), and
thrombocytopenia (7%) [73]. The most reported side effect associated with lurbinectedin
was myelosuppression in the initial phase I trial in advanced solid tumours [74]. The
toxicity profile of lurbinectedin may make its incorporation for LS-SCLC management
challenging, especially with concurrent chemoradiotherapy.
4.1.2. Delta-like Protein 3 (DLL3)
Whole-genome sequencing analysis revealed inactivating mutations in the primary
NOTCH family of genes in 25% of SCLC tumours [75]. Overexpression of a negative
regulator of NOTCH signaling, delta-like protein 3 (DLL3), was found in a majority of
SCLC patients [76]. An anti-DLL3 antibody-drug conjugate called rovalpituzumab teserine
(Rova-T) showed antitumor activity when evaluated in a phase I clinical trial with patients
who had recurrent SCLC [77] OS benefit [78–82].
However, DLL3 has remained of interest and has shown to act as a biomarker of
sensitivity [76–78]. Results are awaited for an ongoing phase I clinical trial (NCT03319940)
evaluating AMG 757, a half-life extended bispecific T-cell engager (BiTE) immunotherapy
against DLL3 [83].
4.2. Immunotherapies
Successes in establishing the routine use of immunotherapies for SCLC patients had
been limited [84,85]. In ES-SCLC, trials investigating the efficacy of immunotherapies
including rilotumumab, ganitumab, and ipilimumab in combination with chemotherapy
trials did not show significant OS benefit [86–89]. The landmark 2018 published study
showed the addition of atezolizumab to chemotherapy in first-line treatment of ES-SCLC
improved OS and progression-free survival (PFS) compared to chemotherapy alone [88].
In 2019, atezolizumab combined with carboplatin and etoposide received FDA approval
based on the IMpower133 clinical trial for ES-SCLC.
Durvalumab combined with first-line chemotherapy is another treatment that showed
significant OS benefit when treating ES-SCLC patients [90]. Pembrolizumab in addition
to chemotherapy in the first line treatment of patients with ES-SCLC was shown to have
prolonged OS in the Keynote-604 study (HR, 0.80; 95% CI, 0.64 to 0.98). However, a higher
significance threshold was set in this study and was not achieved (p-value = 0.164) [91].
Despite ongoing study, there has yet to be well defined biomarkers that predict benefit
from immune-checkpoint inhibitors [85], however one promising biomarker approach for
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ES-SCLC reported by Gay et al. [92] leveraged the IMpower133 patient samples and defined
an inflamed gene signature (SCLC-I) that correlated with atezolizumab benefit. This SCLC
subtype had uniquely expressed genes that included numerous immune checkpoints and
human leukocyte antigens in the absence of a transcriptional signature [92]. Whether this
SCLC-I subtype in ES-SCLC would extend into LS-SCLC patients and associated treatment
approaches remains unanswered.
Specific to LS-SCLC, a phase I/II trial published in 2020 investigated concurrent
chemoradiation with pembrolizumab for LS-SCLC patients reported pembroluzimab was
well tolerated. Patients were followed-up for a median time of 23.1 months with median
PFS of 19.7 months. Median OS was reported to be 39.5 months [93]. However, other
immunotherapies are being evaluated in randomized studies for LS-SCLC, such as the NRG
LU0005 trial (NCT03811002), a phase II/III trial that is comparing concurrent atezolizumab
with chemoradiation compared to chemoradiation alone and its effects on PFS and OS.
Unfortunately, the recent phase II STIMULI trial of 153 randomized LS-SCLC patients
showed no improvement in PFS with the addition of consolidation nivolumab-ipilimumab
following chemoradiation for LS-SCLC [94]. Another ongoing study is the ADRIATIC
trial (NCT03703297) that is evaluating the effects of consolidation durvalumab and tremeli-
mumab on the PFS and OS of LS-SCLC patients without progression following concurrent
chemoradiation [95].
We eagerly await the results of these ongoing studies that will define the role for
immunotherapy for LS-SCLC patients. Studies about ongoing and completed prospective
studies for immunotherapies in LS-SCLC are summarized in Table 3.
















No grade 5 toxicities,
3 grade 4 events
(2 neutropenia, 1
respiratory failure). [n = 40]
19.7 months (95% CI,
8.8–30.5) [n = 40]
39.5 months (95% CI,
8.0–71.0) [n = 40]










HR 1.02 (95% CI, 0.66–1.58)
HR 0.95 (95% CI, 0.59–1.52)
Ongoing Trials
Senan et al., 2019 [95] 600 (estimatedenrollment)
Consolidation durvalumab













* no significant difference.
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4.3. Pre-Clinical and Translational Studies
Efforts to define molecular subtypes of SCLC are ongoing. Gene expression profiling
of SCLC from cell lines, patient tissue, and murine models have identified differential
expression of transcriptional regulators (ASCL1, NEUROD1, POU2F3, YAP1, and ATOH1)
or immune-related genes (SCLC-I) as candidate molecular subtypes [92,97,98].
5. Discussion
5.1. Current Limitations
The primary modality of LS-SCLC treatment remains concurrent chemoradiation
with platinum-based chemotherapy [4,7]. Concurrent chemoradiation has long been estab-
lished as the standard of care for LS-SCLC patients, particularly by two meta-analyses in
1992 showing this treatment modality improved OS and local disease control [8]. Turissi
et al. [5] showed a significant difference in median survival for patients that received BID
radiotherapy compared to those that received a once-daily regimen [5]. However, it is
noted that the findings from the CONVERT trial suggested an increased dose of once-daily
radiotherapy to 66 Gy did not show OS benefit compared to the 45 Gy/30 BID regimen [6].
Through collaborative decision-making with their physician, eligible patients without brain
metastasis can undergo PCI which has been established by prospective studies to improve
OS and reduce subsequent intracranial metastases [18].
There remain further controversies in the management of LS-SCLC. Optimal LS-
SCLC radiation fractionation is still being debated between the benefits of the current
recommended fractionation scheme and increasing it [5,6]. The role of PCI in the MRI era
is being evaluated with the rationale for surveillance with MRI brain to lower PCI-related
neurotoxicity in LS-SCLC patients while maintaining OS [20].
5.2. Risks and Benefits with Multi-Modal Combinatorial Therapies
Further consideration by clinicians is required to balance the risk and benefit of further
treatment with studies increasingly investigating new targeted therapies and immunother-
apies to treat SCLC patients. While the first-line of treatment for LS-SCLC patients remains
concurrent chemoradiation, there is potential for further addition of novel combination
or adjuvant therapies. For novel combination therapies with concurrent chemoradiation,
caution needs to be exercised with respect to treatment tolerability, whereas additional
adjuvant therapies may be more tolerable however may forgo potential concurrent treat-
ment synergy. For example, prospective studies investigating the use of immunotherapy
in both concurrent or consolidation following chemoradiation are underway to leverage
the orthogonal mechanisms of action among each individual treatment and an acceptable
toxicity profile [94,95].
5.3. Molecular Subtyping of SCLC Leading towards an Understanding of Inter- and
Intra-Tumour Heterogeneity
SCLC is moving from being studied as a homogenous disease and towards being
classified as a heterogenous disease (e.g., transcription factor subtypes: SCLC-A, SCLC-N,
SCLC-P, SCLC-Y, SCLC-I, etc.) [97,98]. This distinction is crucial as a more comprehensive
molecular definition of SCLC subtypes can help enable the discovery of biomarkers that
suggest drug sensitivity or resistance and stratify patients according to their response to
targeted therapies, the bedrock of precision medicine [99,100].
Single-cell RNA-sequencing (scRNA-seq) has enabled further exploration of inter- and
intra-tumour heterogeneity, cell types, and cell states [101,102]. scRNA-seq technology is
increasingly gaining higher throughput capabilities and sustainable cost, allowing a greater
number of single-cells to be profiled at this resolution [102]. Bulk-sequencing technologies
used to measure gene expression may not be able to capture the complete heterogeneity in
a diverse biological system such as tumours; these technologies only measure the average
expression levels of each gene in a large population of cells [103].
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Further study using mouse and human models in combination with time-series
analysis of scRNA-seq data has revealed MYC as a driver of dynamic evolution of SCLC
subtypes [104]. It is suggested that MYC can convert SCLC subtypes in a context-specific
manner; with the loss of RB1 and TP53, MYC can promote a pulmonary neuroendocrine
cell from SCLC-A to SCLC-N to SCLC-Y in vivo. This study suggests that intratumoural
subtype heterogeneity is critical to be considered when designing future clinical trials [104].
Characterisation of generated circulating tumor cell (CTC)-derived xenografts from
SCLC patients using scRNA-seq of chemosensitive and chemoresistant CTC-derived
xenografts suggests increased intratumoral heterogeneity following therapy resistance.
Multiple subsets of unique SCLC cells may develop within a tumour and there needs
further consideration of diverse therapeutic strategies to maximize treatment response
before the development of resistance mechanisms [105]. With the era of precision medicine
well underway, SCLC patients have yet to have benefited from the promise of various tar-
geted therapies. Subtype identification for SCLC has yielded promising targets that require
further interrogation [97,98]. As SCLC moves towards being considered a heterogeneous
disease, subtype identification may help select patients that may benefit maximally from a
particular treatment and reduce the failure rate of clinical trials. With more SCLC subtypes
being defined to enable precision medicine [97,98], it is also key for clinicians to consider
how to effectively recruit for and design statistically sound clinical trials. However, it
remains a challenge to find effective therapeutic strategies for LS-SCLC given a significant
majority of studies are focused on ES-SCLC.
As the throughput of scRNA-seq technologies improve in parallel with falling costs,
tumour heterogeneity can be further explored to reveal new subtypes of SCLC and their
plasticity to deliver on the promise of precision medicine. More crucially, the integration
and innovation with radiation in combination with chemotherapy and novel therapeutics
represent the next frontier in managing LS-SCLC patients. While this remains an exciting
prospect, prospective studies to carefully consider the benefit to LS-SCLC patients while
managing tolerability will be necessary.
6. Conclusions
Novel treatment options for LS-SCLC patients remain promising but compartmental-
ized as a majority of novel treatments are tested first in ES-SCLC. The landscape of LS-SCLC
can be transformed with the integration of new targeted therapeutics and immunotherapies
to standard-of-care concurrent chemoradiation. Prospective studies are eagerly awaited
to determine the routine use of PCI in the MRI era, novel radiation techniques such as
HA-PCI, proton therapy, SRS, and SBRT, along with the ideal dose fractionation schedule
for LS-SCLC patients. In order to capture tumour heterogeneity, scRNA-seq in addition
to bulk sequencing technologies may improve SCLC subtype identification which may
lead to biomarker-selected clinical trials. Despite the longstanding challenges with the
management of LS-SCLC, novel approaches to treatment and biology are poised to bring
much needed improvement to patient outcomes.
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